摘要
以药学期刊为例,将审稿周期和出版周期作为切入点,采用官网、数据库等公开途径查询与作者问卷调查相结合的方式了解目前期刊对审稿周期和出版周期的管理现状以及作者的真实投稿意愿。结果发现,造成“一稿多投”始终“禁而不止”的原因可能在于多数期刊没有按照《著作权法》规定完成审稿或明确约定审稿周期,有些期刊即使约定了审稿周期也没有认真执行,且期刊的实际审稿周期和出版周期超过了作者的心理耐受阈值。在此基础上,本文提出期刊应正确领会《著作权法》精神,尊重作者的投稿利益,明确、细化稿约中对审稿周期、出版周期的约定,提高期刊的出版伦理规范意识等建议,旨在为合理解决一稿多投问题提供参考。
Taking the review cycle and the publication cycle as the starting point,we searched some official websites and public database,together with the author’s questionnaires,to understand the current situation of the management of review and the publication cycle of scientific journals and the author’s real willingness for submission among pharmaceutical journals.The result showed that the reason for unstoppable“multiple submissions of one manuscript”was that most journals did not completed the review process in accordance with the provisions of the Copyright Law or had not clarified a fixed duration for review cycle.Some journals did not strictly followed the time restriction of review cycle even they had publicized,therefore,the actual review and publication cycle had largely exceeded what the authors had expected.Based on the above information,we here proposed that journals should correctly put emphasis on the essence of the Copyright Law,respect the authors’contribution interests,clarify and refine the agreement on the review and publishing cycle in the manuscript agreement,and improve the awareness of publishing ethical norms,in order to provide a reference for solving the problem of multiple contributions.
作者
林静
邹小勇
冷怀明
LIN Jing;ZOU Xiaoyong;LENG Huaiming(Editorial and Publishing Center of Chinese Pharmacy,Cancer Hospital Affiliated to Chongqing University,400042,Chongqing,China)
出处
《编辑学报》
CSSCI
北大核心
2023年第4期368-373,共6页
Acta Editologica
基金
中国高校科技期刊研究会医学期刊专项基金(CUJS-YX-2021-4-1)
重庆市高校期刊研究会“渝编-仁和基金”项目(CQLX2020-14)。
关键词
一稿多投
审稿周期
出版周期
稿约
作者调查
multi submission of one manuscript
review cycle
publication cycle
manuscript appointment
author survey
作者简介
通信作者:冷怀明。